A randomised study of tailored toxicity-based dosage of fluorouracil-epirubicin-cyclophosphamide chemotherapy for early breast cancer (SBG 2000-1).

H Lindman,M Andersson,J Ahlgren,E Balslev,A Sverrisdottir,S B Holmberg,N O Bengtsson, E H Jacobsen,A B Jensen,J Hansen,M K Tuxen,L Malmberg,K Villman,H Anderson,B Ejlertsen,J Bergh,C Blomqvist

European Journal of Cancer（2018）

引用 4|浏览55

暂无评分

摘要

•Tailoring adjuvant chemotherapy dosage based on toxicity was feasible.•No significant benefit of dose escalation, except in grade 3 tumours.•Outcome implies that sufficient haematological toxicity is more important than dose.•Individually tailored dosage of chemotherapy needs further examinations.

查看译文

关键词

Adjuvant,Breast cancer,Chemotherapy,Dosage,Dose tailoring,Leukopenia

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要